Article
Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP-RCC study.
International journal of urology : official journal of the Japanese Urological Association - 1 Sept 2023
Blas Leandro, Shiota Masaki, Miyake Hideaki, Takahashi Masayuki, Oya Mototsugu, Tsuchiya Norihiko, Masumori Naoya, Matsuyama Hideyasu, Obara Wataru, Shinohara Nobuo, Fujimoto Kiyohide, Nozawa Masahiro, Ohba Kojiro, Ohyama Chikara, Hashine Katsuyoshi, Akamatsu Shusuke, Kamba Tomomi, Mita Koji, Gotoh Momokazu, Tatarano Shuichi, Fujisawa Masato, Tomita Yoshihiko, Mukai Shoichiro, Ito Keiichi, Tanegashima Tokiyoshi, Tokunaga Shoji, Eto Masatoshi
Abstract excerpt
BACKGROUND: This study is part of the SNPs in Nivolumab PD-1 inhibitor for RCC (SNiP-RCC). Here we aimed to reveal clinical factors for tumor response, progression, and survival in nivolumab for advanced clear cell renal cell carcinoma (RCC) in Japanese patients. METHODS: We included patients from 23 institutions in Japan. We evaluated the objective response, radiographic progression-free survival (PFS), overall...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.